Use of an interleukin 17c blocker in the manufacture of a medicament for inhibiting endometriosis

CN121102466BActive Publication Date: 2026-08-28SHENZHEN LONGGANG DISTRICT PEOPLES HOSPITAL +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202511474899.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2025-10-15
Publication Date
2026-08-28
Estimated Expiration
2045-10-15

AI Technical Summary

Technical Problem

MOR106的使用聚焦于炎症性皮肤病及自身免疫性疾病，研究主要针对中重度特应性皮炎（AD）、银屑病（牛皮癣）等，未见其在子宫内膜异位症方面进行相关研究

Benefits of technology

[0017]在本发明中，白介素17C阻断剂MOR106能够抑制纤维化相关的MAPK/ERK通路的激活，降低IL-17C和IL-17RE以及细胞外基质相关蛋白（FN1和α-SMA）的水平，同时，MOR106减缓M2巨噬细胞诱导的对子宫内膜基质细胞的促纤维化作用，缓解子宫内膜异位症中病灶及其子宫内膜的纤维化，从而缓解子宫内膜异位症中病灶及其子宫内膜炎症的发生，抑制子宫内膜异位症中病灶的生长。

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN121102466B_ABST
    Figure CN121102466B_ABST
Patent Text Reader

Abstract

In order to prepare a medicine for effectively inhibiting endometriosis, the application provides an application of interleukin 17C blocking agent in preparation of a medicine for inhibiting endometriosis, wherein the interleukin 17C blocking agent is MOR106 and / or a monoclonal antibody with 90% sequence identity with MOR106, and the monoclonal antibody has an antigenic determinant corresponding to interleukin 17C.
Need to check novelty before this filing date? Find Prior Art